Previously, we and others showed that the localization of a biomarker, nuclear factor kappa B (NF-κB) p65, in the nucleus of prostate cancer cells allows the identification of patients with aggressive prostate cancer. The gene discussed is NFKB1; the disease is prostate cancer.